Literature DB >> 16137562

Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing.

M A Hickey1, K Gallant, G G Gross, M S Levine, Marie-Françoise Chesselet.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by an elongated glutamine repeat in huntingtin. Improved understanding of the molecular effects of the mutation opens new avenues for treatment. High-throughput automated behavioral tests that produce well-defined markers of disease progression are necessary for in vivo drug screening. We have identified early behavioral deficits in tests of motor function that are amenable to cost effective automated analysis in a mouse model of HD. Running wheel activity and climbing behavior were reduced in R6/2 HD transgenics from as early as 4.5 weeks of age, at a time when rotarod performance and grip strength were still normal. Power calculations showed that the running wheel test was appropriate for efficient, high-throughput drug screening at this early age. Furthermore, the data extend the range of behavioral deficits observed in 1-month-old R6/2 mice, an age when synaptic dysfunction can already be detected in the striatum.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16137562     DOI: 10.1016/j.nbd.2005.01.024

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  46 in total

1.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

2.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

3.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Authors:  Miriam A Hickey; Chunni Zhu; Vera Medvedeva; Nicholas R Franich; Michael S Levine; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2011-10-20       Impact factor: 4.314

4.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

5.  Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Authors:  L Wang; I Magen; P-Q Yuan; S R Subramaniam; F Richter; M-F Chesselet; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-11       Impact factor: 3.598

6.  Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.

Authors:  Jodi L McBride; Shilpa Ramaswamy; Mehdi Gasmi; Raymond T Bartus; Christopher D Herzog; Eugene P Brandon; Lili Zhou; Mark R Pitzer; Elizabeth M Berry-Kravis; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

7.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

8.  Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.

Authors:  Geraldine T Petr; Laurel A Schultheis; Kayla C Hussey; Yan Sun; Janet M Dubinsky; Chiye Aoki; Paul A Rosenberg
Journal:  Eur J Neurosci       Date:  2013-04-16       Impact factor: 3.386

9.  Context dependent neuroprotective properties of prion protein (PrP).

Authors:  Andrew D Steele; Zhipeng Zhou; Walker S Jackson; Chunni Zhu; Pavan Auluck; Michael A Moskowitz; Marie-Francoise Chesselet; Susan Lindquist
Journal:  Prion       Date:  2009-10-16       Impact factor: 3.931

10.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.